RHYTHM PHARMACEUTICALS, INC. (RYTM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 48,502 | 32,704 | 33,251 | 29,078 |
| Selling, general, and administrative | 45,947 | 39,087 | 35,377 | 36,415 |
| Research and development | 42,308 | 36,973 | 37,931 | 30,194 |
| Cost of sales | 5,543 | 3,648 | 3,828 | 2,947 |
| Total costs and expenses | 93,798 | 79,708 | 77,136 | 69,556 |
| Loss from operations | -45,296 | -47,004 | -43,885 | -40,478 |
| Derivative, gain (loss) on derivative, net | - | - | - | 8,900 |
| Other income (expense), net | 1,576 | -644 | 1,088 | 302 |
| Interest income | 3,242 | 3,639 | 4,054 | 4,097 |
| Interest expense | 5,817 | 5,409 | 5,242 | 4,603 |
| Total other (expense), net | -999 | -2,414 | -100 | 8,696 |
| Loss before income taxes | -46,295 | -49,418 | -43,985 | -31,782 |
| Provision for income taxes | 337 | 80 | -344 | 479 |
| Net loss | -46,632 | -49,498 | -43,641 | -32,261 |
| Accrued dividends on convertible preferred stock | 1,349 | 1,322 | 1,329 | 1,302 |
| Net loss attributable to common stockholders | -47,981 | -50,820 | -44,970 | -33,563 |
| Earnings per share, basic | -0.75 | -0.81 | -0.73 | -0.55 |
| Earnings per share, diluted | -0.75 | -0.81 | -0.73 | -0.55 |
| Weighted average number of shares outstanding, basic | 63,684,359 | 63,059,165 | 61,219,918 | 61,011,824 |
| Weighted average number of shares outstanding, diluted | 63,684,359 | 63,059,165 | 61,219,918 | 61,011,824 |